Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study - PubMed
a day ago
- #Pan-tumor activity
- #KRAS G12C inhibitor
- #Phase 1 study
- Olomorasib is a next-generation KRAS G12C inhibitor evaluated in a first-in-human Phase 1 study (NCT04956640).
- The study included 195 patients: Phase 1a dose escalation (n=112) and Phase 1b dose expansion (n=83).
- No dose-limiting toxicities (DLTs) occurred, and 150 mg BID was selected as the recommended Phase 2 dose (RP2D).
- Olomorasib was well tolerated with predominantly grade 1-2 treatment-related adverse events (TRAEs) and infrequent grade 3 TRAEs.
- Higher objective response rate (ORR) and median progression-free survival (PFS) were observed in non-CRC solid tumors compared to CRC.
- Intracranial responses were noted in patients with untreated, active brain metastases.
- The study supports the potential of next-generation KRAS G12C inhibitors to overcome limitations of earlier agents.